<SEC-DOCUMENT>0001193125-13-329989.txt : 20130812
<SEC-HEADER>0001193125-13-329989.hdr.sgml : 20130812
<ACCEPTANCE-DATETIME>20130812080535
ACCESSION NUMBER:		0001193125-13-329989
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130812
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130812
DATE AS OF CHANGE:		20130812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		131028220

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d583222d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>OF THE SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): August&nbsp;12, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>GALECTIN THERAPEUTICS INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nevada</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-31791</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-3562325</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NORCROSS, GA 30071 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) (zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s
telephone number, including area code: (678)&nbsp;620-3186 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION&nbsp;7 &#150; REGULATION FD </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;12, 2013, Galectin
Therapeutics&nbsp;Inc. (the &#147;Company) issued the attached press release, which is being furnished and not filed, and is attached hereto as Exhibit 99.1.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information in this report is being furnished pursuant to this Item&nbsp;7.01 and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934 (the
&#147;Exchange Act&#148;) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date
hereof, except as expressly set forth by specific reference in such filing to this report. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION&nbsp;9 &#150; FINANCIAL STATEMENTS AND
EXHIBITS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Financial Statements of Businesses Acquired. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Pro Forma Financial Information. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Shell Company Transactions. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:26pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit<BR>Number</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated August 12, 2013</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galectin Therapeutics Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: August&nbsp;12, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Jack W. Callicutt</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jack W. Callicutt</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d583222dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g583222g04s63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FINAL for Release Monday, August&nbsp;12, 2013 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>for Fatty Liver Disease with Advanced Fibrosis </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Norcross, GA, August&nbsp;12, 2013 &#150; </B>Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced
that the U.S. Food and Drug Administration (FDA) has granted GR-MD-O2 (galactoarabino-rhamnogalacturonate) Fast Track designation for non-alcoholic steatohepatitis (NASH) with hepatic fibrosis, commonly known as fatty liver disease with advanced
fibrosis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galectin Therapeutics is currently conducting a Phase 1 clinical trial to evaluate the safety, tolerability and exploratory
biomarkers for efficacy for single and multiple doses of GR-MD-02 over four weekly doses of GR-MD-02 treatment in patients with fatty liver disease with advanced fibrosis. The study will enroll 8 patients in each dose escalation cohort and there
will be at least three cohorts and potentially up to 5 cohorts, with a maximum of 40 patients at six clinical sites in the US, which each have extensive experience in clinical trials in liver disease. More information on the first-in-man Phase 1
clinical study of GR-MD-02 is available at <U>http://clinicaltrials.gov/ct2/show/NCT01899859?term=gt-020&amp;rank=1</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Our
preclinical data has shown that GR-MD-02 has robust treatment effects in reversing fibrosis and cirrhosis. Fast Track designation enables us to expedite the compound&#146;s development and review process, with the ultimate goal of bringing a
first-in-class treatment to the millions of Americans suffering from fatty liver disease with advanced fibrosis,&#148; said Dr.&nbsp;Peter&nbsp;G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc.
&#147;We are very pleased that the FDA sees the clinical value of GR-MD-02 and seriousness of fatty liver disease, and we look forward to working closely with the FDA throughout this process.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA&#146;s Fast Track program is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and
demonstrate the potential to address unmet medical needs. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About GR-MD-02 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">GR-MD-02 is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. Galectin proteins play a major role in diseases that involve
scaring of organs such as cancer, and inflammatory and fibrotic disorders. The drug binds to galectin proteins and disrupts their function. Preclinical data has shown that GR-MD-02 has robust treatment effects in reversing fibrosis and cirrhosis in
kidney, lung, and liver. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g583222g04s63.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Fatty Liver Disease with Advanced Fibrosis </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, has become a common disease of the liver with the rise in obesity rates,
estimated to affect nine to 15&nbsp;million people, including children, in the US. Fatty liver disease is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time,
patients with fatty liver disease can develop fibrosis, or scarring of the liver, and it is estimated that as many as three million individuals will develop cirrhosis, a severe liver disease where liver transplantation is the only current treatment
available. Approximately 6,300 liver transplants are done on an annual basis in the US. There are no drug therapies approved for the treatment of liver fibrosis. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Galectin Therapeutics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company&#146;s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development
expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver
fibrosis and cancer. Additional information is available at www.galectintherapeutics.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as &#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on our current expectations
and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. These statements include those regarding plans, expectations and goals, expectations and goals regarding the
clinical trial, our FAST TRACK submission and the potential benefits of a FAST TRACK designation, potential therapeutic uses and benefits of our galectin inhibitors and further related studies and potential partnerships. Factors that could cause our
actual performance to differ materially from those discussed in the forward-looking statements include, among others, that the receipt of a FAST TRACK designation from FDA is no guarantee that we avoid delays in the development of our drug product
and provide no assurance of FDA approval of our drug development plans and of the grant of marketing approval for our drug product. Future clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove
time consuming and costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Regardless of the
results of current or future studies, we may be unsuccessful in developing partnerships with other companies that would allow us to further develop and/or fund any studies or trials. To date, we have incurred operating losses since our inception,
and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the
year ended December&nbsp;31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g583222g04s63.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Contact </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galectin Therapeutics Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peter G. Traber, MD, 678-620-3186 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President,
CEO,&nbsp;&amp; CMO </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>ir@galectintherapeutics.com</U> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g583222g04s63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g583222g04s63.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/`#-`P$1``(1`0,1`?_$`+D```("`@,!`0$`````
M```````)"`H&!P0%"P(!`P$!``$$`P$!``````````````0!`@,%!@<("0H0
M```&`@$#`@0"!`D,`P````(#!`4&!P$(`!$2"1,4(146"C$7(C(C.4%10G;6
MEUAX&F&1,R0UM;;&A[<82'.X&1$``0,#`P(#`P01!0```````0`"`Q$2!"$3
M!3$&02(446$R@3,5!W&Q0G*RPB-S@R0TQ$6%%D8(D5)#4PG_V@`,`P$``A$#
M$0`_`+_'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(
MX1'"(X1'"(X1<1>O0M2%:Z.:Q*W-K:D4KW!P7*"DB%`A1DC4*UBQ4H&60F2I
M4Y8AF&#$$``!SG.<8QPBJ-UQO1MOY^]Q;FHS2*\YEIQXPM7W1&T6YLW4H2&_
M8G9-]<5"]*T1NKY@YHSC*N8Y,!J5K$JE$7A<C:2`*EHC#5J=N*(G01OPQZ!1
MQL(*S`K>D$L+"`U1:TFVLVF=;@7.N,X,,?C;)_.,B2HG8Y3CU<Y1G)2`#S^@
M4`/Z/")3'EAN/R'^)6@'-KJBXK#V)UIOJ9UM4E;7=93^F==G])K%DMA1P]2C
MD=A_)QG7C4T[A:1X;V9S?"OJ)C>C$Y"MQ6E&I\"(K6W"(X1'"*GW]VFT7S0F
MI;)MO0VYVW%0.$DN*`TC-*<@5SOL5IE[B<CA,\6G.:.-QT#4[-<D]_%"/<&A
M7C3K"CSL&$]W8()%:HU_4*%=#4DJ5J#U2I345;*%*I4<8H4J5!T-9C#E"A0<
M(9QYYQ@LB&,8LB$+.<YSG.>$6W.$1PB.$1PB_!"P'&1"S@(0XR(0A9QC`<8Q
MUSG.<_#&,8X1=%%Y3&YO&V*8PY^:)3$Y0TH7V.21@<$KLQOK*Z)RUC:[-#FB
M-.1N#<O2FA,).*&(LP`L"#G.,\(HYO&ZVMS#M3&]+72PBDVQ,KBALQ9H5\F?
M#$YS6!$Y.I28^1EMPH\C>5C0SJUA*,U2$\Q.0(6`_$&!:M_,\<SE&\.Z2G(.
M;<&T/2A/6E*T!-*UH%RR'L?N;([3E[WBQB>VX9MMTMS:W5:VH96\M#G-:7`4
M!-/;257-HN)HX1'"*%GD7M:>4=I!LI;=8/XHM/X%6S@_1:0@0-KH)I="%R`H
MM7AO=T:]L5Y"6<+'8<28#/7\.O3FG[@RI\+ALC*QG6SLC)::`T-1X&H_U7;?
MU#]M<+WC]<';_;'<4'J>$S>0;'-%<]E["UQ+;F.:]NH&K7`^]0'\==:^4*WX
M:P79N=MK-8'%9(C3/,4I6+5U3S'-'%C5DX4H7B?R157RHZ*E+R!!,+:TA.%X
M21X$>H3F=2<:/@,?N7+A;F<OE/9$X5;&UD8<1X%QL\M?]HU]I!T7=?U\=P_X
MY]J\K/VC]4_;&'F\CCN+)L^;*SI,=DC31S,:(9($UIJ#,]VW<*,8]OF+'77=
MW3Z)ON(4^[,U"ED2(PMN4I5L\8SCRE8,8*$6Y+R%`D"=9WX_:X,,!D(^O=C'
MX<YL(WTT!(7CI\@>\OH!4DT'05\![O8M/;0UEMK*X>JLC2W:AQ2.@T!CTV5\
M],]82J$3)(,(E!:>(313%CU[,K4EX[4PE2E:B.%G`1#(#G)F+F%@-'C16FO@
MJU#EY4/(@S.3BSNUYN3<[-"]8UNC<KKZLRE3>Y-RDU&O0JB_H_/IJ4BLD98P
M]<]!!SCDG:C/@L=SEUQOEC\@(2QB#L`JQG`<YQGZ!K+\<8_RP[IQLQ^Q+BKF
MGSMS_*?ZC]UGYS^7GSOWOI$]?F?TW[[W7H^GZ'7W?Z?;V]G\'3I\.0_'W+*D
MC?<X['2;6[PY[+N$,7JFF3W"HA&OZ-U1J#$RE$S6?(DZ2<@+-*R$S&72NVYW
M0Y[<XSC"KKU^'*(HN?9\5RQ0_P`0R.8-R4@#Q;.QUR2R0K`E@PH4G,`X[7;:
MG--QCO&2D;H<$18<YZ!$:/./UL\(K3_"*+VYNJ,!W<UNL36>RW!V9XI868FJ
M.?&`MN,?6%WA$VCD_C3RS_-DBY`%<WR*+)3,9,*%C(<"Q_#PBD5(7]DB;`^2
MF2NB)CCD:9W)_?WIR/`E;F=D9D1SBZNB]29G!:=$WH4QAII@LX"`L&<Y^&.$
M27]5O)[L;Y'HQ/KD\?\`JW5CIK-%)])*XA=R[3WY+J@=KI>XF!*%\>(/6=>4
M3<+NQPTI4K`40N>5J14>/N#E&484:6`BSK1+ROMVT.T&PNA-\T:[ZL[PZSH4
M\CFM4*)NUVA!IM7ZSY`)#8E5V2VL\9-?V)4DE;2K$G6M3>K)2NJ87:,6%(4Y
M$KO[R?\`=(Q;^^'3?_`=Q\(K)]'.[5']::??GUR0,K&R4;7[N\O#JL3M[6TM
M3;`6E8XN3DO5F%)4*!`D)&:<<:,)918,B%G&,9SPB7+1_D?V`WO13FQ?'AK/
M7,]UHB,MD,&BFQ^S%X2:DH]?<CB2HUMDJNDH/"*7N*7+X"V.Y64@)"]X:"U:
M@)I9*4>2#NPBS;0?REP[<.X-@]2K-JUZUCW>U6<BTUSZ[R64M$V2J(ZJ$APV
M635<_9T;2DL&NW,MV0F>ZR@0*DP'%)DU.$M208:19)N1Y,Z_UEN:I]1ZPKF4
M[2[P7LF4NM9ZS5R\,C`K;HDA+6'.5F7%8#_DR/U#5[<0VJ1#<E9*Q6H]N9[5
M$H],S("**6W_`)7MFO&?$:ZNW?\`T^K1OUKG-B,=9R6QM4MB)/=,OIY\DB)S
M<&==-*^L*A:5`_Q\Y.T*`&*FES,&`XK!82C##DY9I%@OW`?D`VVU$\?5B6_J
M74D6D%=36MH^V/>TCQ9S<RKZF)N1\0P-B60BHC&K$EF4L4)Y2D5(%PE:5&UF
M'X/.)4>W&2(BV#XC+QW!'I+X^82ZZ*JVZFTNI5"-Y5XE;/5,^K'&-M=)L1S'
M*RJT+0)))[N6F)$^`MYRD"A&8MZ*#/V1@N$48&CRW1&0^:77'3:TO%3)J'VA
ML6+2%O;M@;LE-0+K%CE5X@EARYO50\VKBK';I`Q/ZZ(+&_J3*"L)LF*2AAP,
M)I.8IPL1V4,YT3#F-;:'T%P!\*]:+;,YWFH^(?P$>5D-X2202.@#W;3GBE'%
ME;2=!X=0#U`4]_+KY.[7\75,K[X8=()]LM5#"UM9TULQAM:`0.'UT]2&1!BS
M`V2MK7%R6QSDRQV6(@B6HF(]O!E<46)0$S(L!E+4K&*.\IES;KT75=F:#:B(
MKP=I55\$EUHR^RKK(I?7.J;&E$5;9!(J1:+/Q7\ZF=P6'`G%48WO(6&+B:FE
M1@)*U>G6X-1%$77:">81SV7V^O#QV[4:QONG>[M&Q\4V5U^.P6JV:ZL6!8$R
M&8E-?V&VL47$LP-LD[:O+3&H?VZ!5ZQ9N1DJB$Y$XZ;0B*6-&7"&S=D122+N
MQC<8Z,;D7ZS>XX:W1$\)"%I'7`5*7"]O*$,H74LT(<A'C(<YQG%-#%D1F&9H
M=$:5!Z&A!U^4+9<1S')<#R#.5X>9^/R,0<&2,-'-O8Z-Q:?`VN(!&H)J""`4
M@SSA;<36$XA>KE?/:^.$3.,'3>TG5I5&HW%SC:IQ6LC!#2U:<0%"=M<U+:L4
M.(09#E04625G/IC-`.;`P'S%:IY\$CO5G3:Y-P'68,-,)HF8K@K:T.CZ7)W[
MZ?("C?%2Y(A]D(#>O]R9DYN,[\=H<`QT^.>O3F=SPSJK0">B:Y7>@?EOJ>I)
MC1U>6'!HO7$W4%*'5H;[./`L;<9`<4YIHJ[9C^5T422(HW`7("$1/N@EAZY#
MU'WXC)"3<>JNM=T4</\`\2MY/X4-2YS^.<YL8W.<YS^.<YS'>N<YY=O,]ZI8
M5\&>$C>098PX05'U$'.,=;%,Z=<X_F[QOL]Z6%6V_IYQ_+'Z4Z$?-_H/Z>[?
M5_U;YC]/_+>GK]G^@]S_`"^W]7X].1/&JR)'OW.6MLMV5\.VR#;!6U4]2FGE
MT(V`2LR).:J5N#)6+\6HG0DY1.!&"&TUZYNR_IC`LBPDR'&.HL<HBAI]G#<K
M!//%9(ZK2K"?J:BMD;'9GIK]3&51++/F^/3Z.NXROU@)'-8[.2<H7X",0&XQ
M\0YZ$5K1];!O;(\LQ3JZL1CNU.#86]L1Z=,]LXUZ0Y*!U9E"M*N2IW5O$;ZR
M<9I!Q8#@!R(`\8R')%Y_/W%.Q/DM\2UZ:XQ36KR:[7RFO]@8+*78+1;9U/22
M1QN40N0LK,X`2R)CJ>,`6LCLDDB,PLL]((\@\L[]L,`P`*(KFFG&KE@TG4BM
MGV"VJO3<>4V)#8RGL)5L`.MU4.0+@LS@7*D$'B$0@$53,L6D(WLTE4D<E#N,
MU*F(`,[.0FB-(H54QN_6\M=I/IKX7M;JQL6&:^.J^'V!<Z/VM,Z#41*UQYSP
MNBK&_0I@<WN\+`,6KC5BQGAK:)'W'X.6O*3)X1B(DDZ4,EMQW[O+:EMO"PXO
M9UFYTL2JY+*X1`#:PB!N7"N-;5[>R1Z'J95-G%(TQMN.)0E'K'5:L6X3>X.'
M@PS(0D4L?O)_W2,6_OATW_P'<?"+>_G@L^:53]NK:KO!E*M`YRFBM9JT=G!$
M(0#DL/LF359#YF2(8,XR%.\1EV5-YO\`&4L%CX=>N"+'_!_HZWS;Q.Z.2Z-[
MB;LU^VR6FRGLZ'5E=#!'(*PO3E*)&KDR./,AU>N9S>ES)#58Q@&H-%DX0\Y%
MG.<\(F`T5X:-6J'W76>0AMGFREB;3O$><8M)9_:]Q&RLJ5L3A$6^$%MTC9DD
M?96]P3-;`SH0)"^T!9)R$@WMR87@7"*OGX3IDY7A]RUYI[/LPTQQGT,;+4K2
M&8<Q9,5,$"A=]PRMFIM;2SL=R9,VQ6"M"7.08#C(1YSGKDS.<D5T6=U[`+2C
M2R%V;!X?8L.<3D2APB<[C+++HTO/;5A+@W'K&*0(G!K5'(%Z8L\@0RA"*.+"
M,.<"#C.")`GW50`%>$#:(HH`"RRY3KL`LL`<````+_K<(```'&`A`$..F,8^
M&,<(F4>)S]U[X[O[E&L?_9N'\(J\6]80X^[S\5@L!#@0M5'KN%C&,9%VL>W_
M`&]V?QSTZ_#A$T3[F+]R)O+_`#=J3_O_`%3PBDQX3$"%N\1WCI3MR)&WIQZD
MTTN&0A3$I"1K7.)H7)S6C*3@+`-6Y.2LU0H-SCO./-&8/(AB%G)$B%&+(/O.
M';`,Y!@[24L)N`Y[?5QBEFP6,&=.GJ8P(H.?CU^(<?Q8X17$75X:6)'EQ>W-
M`T-X5*!&)<YJR$*0*MU7IFIL3"4J3"B<'N#FM)3DASGN,.-``/40L8R15G_/
M'04J*G%:;*M;>J7PM5%"*OF"Q.48<5&WUM>'5XC2MQ$'&<)4$A3/1Z<LP70L
M*E*$&<]QQ>,R8':%JL>/%*WTVW>LC25]G;_7$5A,I5V`T,;.Z$S4M\,(1$,*
MUP6I34&&1U:C,''&.0PF>H(8>W`>F,9Z]<KV!_56@T3XO'WY(MLMT+P!"U]3
M50RUA&6I:]V5,V%#-,*64@:4XF.L[>J<9*K;?GK\\"+],HPLP7M"5!O;T!UY
M@DC:QM:FJO#B4]48NT`Q8_$(1"_S8SGF!7M%2![U2Q>?N4-PFYR>49-(ZX#+
M;7-U1$B,265WC+0+5"8L1G;.,8[Q@)QD73ICKGX<Z??]8?+-<6[./H2/N_;]
M\OK;B?X`?57/!%*_F.?#I(V.-'8E*N:":?J_357#_JY?^57UY[9)\S_+[ZN]
MIT.]C[_Z<^<^VZ>K[CVGN/T?U^_L_E=?CSMC==Z7?H+MN[W5I5?*WZ+A_J7Z
M%N=Z?UVQ=I=;N[=>E+J:]*5\%G*M(E7I5*%<F3K42U.<D6(U9):A*K2J"Q$J
M$RE.<$91Z<\H>0C`+&0B#G.,XSC/)"T:J?IO$;N#X@]SK"W-\/$>B=WZUWCC
M`=B/'1-9FAKIU"B3KE;PE44-8,@,#%"5476K58V`EU-(.:R%9R#_`%].?CT"
M)OD>\G3TZMI)#QXWO)S&YW@HHI9!56MC(O(+=/2#E0D16:@LDRGUB$"C.0EK
M3'Y.08#&!Y[.N0X(J^GD5\+?DZ\YFR<+V%O4ZFM`J;J.*D0ZDZ4E<G,O2XP-
MBI]/D;]*[%_+(0:Y;)/*U6$P3DB&0JRF],E3I_VQA1J@XBM0[MTK95]Z2;-:
M_P!02XF$VI:NO5E5E`Y<<K6-B1IE4GA3FP-2A4XH`&N#6A4JE."CE)`1G)BC
M!&`"(0<8R15L/`RN\D7CSU0>]`K$\3=W.%IPVU9_)XG;1,^IJ#Z]RQ',E:-8
M8YV):SI+%[@4-E4D"(`ICK/*E2IJ)3`*2^L5Z8R+`G76[R?:5^>-^\E4_P!4
MY'O#&-B];CZ_=P:6MT>96"NIP;%87&F6O5A=M3=F<4L?BZBNF\@^4NYJ$MS1
M+!N&$Y!P#6PHBV5]P!4'DRW_`-#Z<TU@>AU@V)?+9.::N2[[8@LLI6-ZZHI*
MUU=(<RF(5:?,[C(L6389Y5/!MF5"YJ0$Y^6'&@&:`PG(B)Q\-J9P\BGC>EVG
M>X6KUTZP"DU&Q*F)RR6*OJ=[5?4K;%6KVT]JYZK>P)\VNR6%S)C3.*`YR*;3
MA*4Y/>E[>_&"):7B_DNZ'AGIT_Q\;DZG;'["4_5DREZC5[;/3:K';82)2BN)
M?)'&4"BMBUY#E*VT:U?VV0O"M01E6W*$O8L$E];TTA*I61.5I.UML-C;N9+#
M,JJ9ZL:@PZ(/Q1<-NYBBB/8+8NPY%A$F9W5SA*%;)E]'5;6B%,I/)+6KDLFD
M+HL+PH1(42/.%Q$DC:7QV;9Z">6Y3YC?'S4BK9:N+P9W*+;LZFQ9X96"T5;?
M(RF$$KG-1%2!:V,\K6.;O&FZ0Y;\J`K_`)\D-!C!B1>8)&1-=*\BMJ79%EL9
MU=T0W4;;LD#:H;H\JVNH)_UIIRM'U4#*8N26O.9\N28>(]%ACRK4M\1)D3HY
MX)PF2EX$<$X!%A'EHT+NK<[Q!7!IM&)N*T]AU=;5@L:9I*@LD0':]G5+*8;.
M%ZAR*0%(8U&%5BKHLI*)+#@AO0GK2PB&`D`AX(HY>*+:[<MOU7U%U`E/C/VC
MJNU-=8)7%,WO85WL[#6E%-]=U''B(TX32JI>J>UK];LYFC,P)RF=D;6L"$#H
MMR-8Y)V\G"HXB6GM)7GDAMWSPZ?^3:#^+39O_P`?-::S15>^L$@GVK;7:<H2
M.;?<220R-GCJ>_7!B2":16N'*5(>Z8$L^7B[S"/6#Z9$RWSN%[;;=^-^;ZI:
MRZ%[#V+8^ST(K![7*W*0T!$F"E"VBRXU-7J*V,J=KGRH63]"DB/H92,I;FV9
M$L`/#@+`!AX120\.+QL=5GCYIK7W8W3F\:.M'4^A(=`5B)]>*6DC+<"F'L[F
MV(2ZI=89:CYZSJO0L:;U2'PID)(4KBR\'F@P8<$B2`&N_(^7]P>=Y5`>+39_
M_P`;3JC#3`XY]>ZL?F^)MQ6)42^KL1?-^_3H1XD)6#/8?./4]CCN]7U<^CPB
M>+YV'MRQX9=YI,C*>HJ]%4$3(4)1J@M#(XR[D2**NB/`U;0N5%(GQC7@!^U2
MJ3`E*"NXHT6,!'DB1%XD_NH=6]BZ>9M9/*LY,596NF84D-7W++6+#M1E[-8$
MH$6'&?A3(5J>NYDN`7@3E[U,&/*3>Y26I29'A&4!IJ$3?L::>$V?]MEQB[:<
M^C5N/F>`0O;.-YK\Q.;VGY$2H+F2[*%%VC_T9*PHLL.>F,!QC&,9=Z3VJVT*
M(.Z?W"7BC\55+/E2Z3+JSV'N=,G<2HC5]$N8)#6J"4FE!(+DMOW,U'.#0XID
MQW3*DI&XNC\K]'!&<)@"PI*QEQ<:NU*N`IT3!O`+L-;>V'BPH_8V]I8KFUL6
M],-B)?,7]2`"<D:Q7L%9R=$UM+>3C"5GCT?:DR=`VHB<!)2(4Q10<=`=<T5S
M/C'V0J%<I_V[*OYP2+_>R[GF*7YQWWQ^VOTK\=^QXWYB+\!J]0C_`-<_^BG_
M`"+STA_#OT/XJ_.K_?O\W_>%NODU<01PB.$1PB.$1PB.$1PBT'<#!.\%RF<,
M]GR&+QZ+53*S4$2CZ&/`"NF:<M4ZII.[.CLRNRT\IN1HBTY",H11`LFFC-"9
MGT^R#EQS^:9DCFQMB=1HIJ[K4D@].@'3K6JY!PV1@5BP)L6.7(ERXZR/+](S
M1I8UK7-`J227&IT`%-:Z+TF7VU;6N^JU[S.XI.].5C:ZQJ0V4P+6F'E-;W,I
MM&8P\IY4R?+8VWG1U6QK@+`EIBA#1&DK.T90LE%BQ!X9V7E\?BYTTSBZ3'!>
M*-H7.#3<*`4IKITUZ:+?=\1\1Q'<?+<!A843(L;DGLA>'27-CB>]IC=<\AX<
M+:N/F!;H=2N@TKVI'.:RHN+6T\RQVM2S?SD2L,S>HHG:6.?.%63N5HWAL0KF
M1`W-!3VT11O*49QA&C2JR4YPTPS<E&X#9P_*;V/!%E%YRI=RCBV@<6.<"`0`
M*AHKT`-#2NJD=[]IC!Y3/R^(9"SB<7TQ?&V0N=$)XHRUQ#BYUKI"1\3G-):'
M`5"WK"=N*5L5\)8H6].<B/=6&>22)*VEI.<$,Y;*T=T[%,114Q"8H/4*4#HL
M*`F*5%I#'0LS!Z'"E.$9H9L/*X>0^R$EQ+7%M!4.##1UM/8>E:7=6U&JT.=V
M?S?&P&?.8V-K)(F2!SJ&)T[2Z/<K0`%H)<6EPC(MDM=0+CP';:N+.A;7/X5&
M;<=XQ)$\#40QPS5TJ0ES8-A9<BVK$>-7I$R;`&@YH4!=SEIB-.U!``U08`@X
M@TVD'*X^3")X6RF-UMIL<+KJTI4>%#=6@;U.A!-W(=H<EQ>:_C\Z7#9E1&42
M#?C.ULVW7T)/F#AMAH<9-0T%S7`?R.W"I_$4K28(@S1Z:[5M)\I2-$L40<G9
M<EM&..4H97>)/Y2/U"&<],]0UR2X5F&9;QC39,"?DD03<CRV)M1S"\MEE,8H
MTDW@N!:?9JTBO33K355'9G,^KRL-^PR7$Q&Y+[Y&M!@>UCFR,KJX%LC'6@7B
MM+;JA<O&W5+%1IP?G%X<V1R:;83T6YPA];,M,V0V\M0)WE!!E#6L/+0X7.$;
M5E.Y"P*H36:SF86X5>VP(S%?I;#$9D<2'"7;+2*.$E*AM#I4CS`UMM\U::JS
M^C^;.4W'C8V2)^(<ILK'71''!+3*'`5H'@QEMMXD%EEVB[6+;0U),#*P)9'%
MZ..MR2V+"HD6;'W(KMF=5(9&XS>+O!WI"3M3DV)HBY"*,&/*1:%+D28XT!A0
MC+XN3Q9MH,+JRN>UNA^)@)<T^PBT^XTT)TKBR^U>8PAE.G:P-PXH99/.WYN<
ML$3VCJX.,C*@"YMWF:"'`8@Z[@P,#91#Q%8U-YBWWU;LNIUC$WL>6]6PR2!(
MK%42T+\@>#D*H@3<LK%T3@"`(@GB)R,(_3[1"PNY:"V!\37O;/*Z,4%*%H?=
M4&G2QP]ZF1=F\@9<^'+E@ADX_#CR7U=4/9*81'86@@U$["?96A%=%\,5_02)
MN6R#M+['G3FF@=SPZ!'Q640I*UFQ"3S:)5R1"JWK).RLB-XGJ2=.,J0K4"@T
M:X\Y:\B*P<$DK`2J,SX(G9#YI'D1S-;:YM+2YK+6,H*NN+@0==74K0:5G[>S
M\R+C(</&QVNR,*2421REVXR*28RS3ESBV(Q"-S7@6@-C!MJ=<N>MG:_CB%O,
M?V:?L[\Z2B41!MA3A#EZ>8.KQ#8P;,Y#B.M@C/;R].GC!652<;,>X9</B4DP
M>>`PH&9_)01M&X)`\N<T-+3<2T7&@^ZTU%I->@J=%#@[6Y')D<,=^._'9$R1
MTHD!C:V1^VR]W6,E_E.X&6=7VM()@%Y]#P*O#'Y`5)7?Z2C7U<>7Z@!E&=AK
M]'3`=Y9F`F%C[1?$(L8SC/PSR>#45'0KCCFEKBT]0:+QC^55$<(CA%Z]WVO'
M[CW3_P#^2^?_`+!6GPKF?&/LA4EI3_MV5?S@D7^]EW/,4OSCOOC]M?I7X[]C
MQOS$7X#5ZA'_`*Y_]%/^1>>D/X=^A_%7YU?[]_F_[PMU\FKB".$1PB.$1PB.
M$1PB.$6%V+&72:066Q%F?$\:7R=@=6`M]4M`WT#84[HCF]2K`U@=&;W2@I.H
M%DK&5``A,Z9%@6,9#G#D1NF@?$QUKG-(K2M*BG2H^VIO&Y46%GPYDT9ECBD:
M^T.LNM((%UKJ"HUTZ>SJM;ZSTLOUUU]JVA\S(N;%U-!6"OV&6'QL#`I<&>+L
MZ5G9U3PT)GIR3FN6"$@1*!D'$%G"S^B`OD?CL-W'X$6#??M,#0ZE*AHH*BIU
M]NH^1;/N?FX^Y.XLOG]G8.9D/F?&'W@.>XN<&N+6D-J=*@D>)*TC6.F"RMP:
MMD@M<U[(UED%SOR4)T'2(3)KFY"90F6)%YA,B.PRACR:5J`IQDA-R<(!>3,9
MZ"P*%C<.['],-VX8SI#\/Q;E>NNE+C2GRK>\IWLSDCRI]((W<I'C,-)2=KTQ
M801Y!=>8Q4&E*FGA39M$Z_OM!01KJ>+V(2NK:&H90V5^VN40(,D3:U/+FN<8
MZU2N0X>_3DR*#E+LI4@DR5K4*TY9?N33#`C,,DX.!)@P#%BDKCL!#`6Z@$D@
M.-=;:T%`TD=35:OG^X<?N#/?R^5C%O)SN8Z9PD-CG-:`]T;+?(9:7.N=(&DF
MT`4`PE!J6_-.ME):\--R.2,BG'6OS%D@Q$B<-MG1."&F]8'/XHFD23WL:DJ;
M)6'`I,X)P'F)P=X1$"-3F81Q3V\=#@-F($);4VZ/:W[ES:Z@^-"*T]E0ITG=
M^/-W-G=QS832[-9+1FYYH))?^6*0L-'L-;"YAH":$.HX1ELZC7V@X]K-7S%-
M%TKPO\@PK>:7!+5!HTD*:)N;;<ODQ,A;(89AL!&6^3SK",M6(300F2J4Y8>T
M9>3!ZS)PI,&/&QV/+ZY^X#9\(=N.-0W2@<ZE?+0$>RJY1Q?/8_<&1RG(SP-A
MM[=].X'(UE=%Z>-A8Z3S7ED5Q;^4)<UQU!H)`':2(U8G&9K;".-NMPV?9MKO
MKHN,$E1<B;QZORJ>:(B&#">C#SH"1403&49(G7YB8:>-;[L*CMP'8'A@:S.D
M_7#DB>ZWRW!NV&VU^';\M+JZW5JN/#OE[+<*/&`X-O%.P-J\WF)\WJ'2;MM-
MTY%)0;+``([+:UVW.J0ELU<J7F.;'0(K"IBP9'-VIS.@Y:R).**6PB75Z[Q<
MR+II&UN2="CCTN&)"IRZFJBU:8L9PCP"&7F5/A2S.AFW`,B&0N!M\IN:YI%M
M0:4=H;JU&M>BT^!SN'@Q9V%Z9SN.S<=D3FB6D@,<L<S7[A8YI)?&+AMAI:XA
MH:0"M2,.F3O'(%2L717":LDM&;#V%?<8ESI`D!I+L.RE%MY?HQ(HZ@D3<G49
M(1W&XA3K4JA)V')TXQ)Q`"849%9P[XX(8A-62#(=*'%HUOOJT@$?]AH01T&G
M@MQD=ZPY/(9V5)A!N-G\=#B/C;*06[(Q['L>6.(J<9ES7!U07"ZM".7,=+RY
MNHNMQ=[+5D/-FWC2^PL-=&V)HTXZSL.B6VOVZ%F83'O2M/+V94"N$67!,HPE
MRH"H5!+&3ZA62$W#[YF<^0WR3QRM(;\#X@T-\?,/(*@TK4]-*687>QP6X,<.
M*#!BX&3B2-=(3OPY3IG2ZAH,;AO.L(NI1A(=0W9=>.M;SL-7V8%9DPA[RA5J
MW-:M2'5@2>U-;B<S)F^-2&$&F2O$OADR@CL6:ZM;NF>,K2UIP@]P2.TL.;-X
MY_(0;&2]CFDD_!H#2@+?-<US3Y@X.K7W*'P7<T/;G(_2'%PS,D`:`1.0YP#B
M7LE_)[<D<K:1OC=':6@&EU2>LW*U`;=Q=*;>TRD-B2.,-EN5BEK5SLOV".2R
MA(6F,:339"H0K%#<C=G5<-J[C^XPK`QFB%C.,].;*-MC&L))(`%3U-/$^\^*
MXMD2B?(?.&M8'O<ZUHHUM23:T>`'0#V*I)_@?*)_M_6U_4A#OZ=\O6%'^!\H
MG^W];7]2$._IWPB/\#Y1/]OZVOZD(=_3OA%:R\:VC#%XX-,:HTXC=B/-ILU5
MF3D:.<O[$@C;J[XF\]D\[.`H9FU:X(TH6T^2B3%]IP\F%DA&+/<+..%4&AJD
MTN?VR%:.2US6BV[L<D3FO<%PBPUA$1!)$O5'*A%ASE]QD02LG=,9S\<XQSK9
MWU<X[G%WJY-23\#?'Y5]%<?_`-#.X,>&.(=KX!VV-;7U<^MK0VOS?C165/H\
MG\OOH#WQOH?1OT?\S]$OU_1^2?)??>W[O2]7L_:=G7MZ_#KTYV'LCT_IZZ66
MU^2E5\__`*5?].?3=@O]7OV5-*[FY;7K3PKU69<S+4HX1'"(X1'"(X1'"(X1
D'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
